- Price is above Fair Value, showing premium demand versus the model.
- Latest weekly return ranks in the strongest part of its sector group.
DXRX
LSE
Week ended 07 Aug 2026
Weekly Investor Report
Diaceutics PLC · Healthcare · Health Information Services
Latest close
153.0 GBP
6.6%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -0.6% below the Trend Line and sits at 50.9% of its 52-week range. The latest completed week returned 6.6%, after a 7.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal.
Setup score
41
out of 100
Latest Close
153.0 GBP
7 Aug 2026
1W Return
6.6%
latest completed week
4W Return
7.4%
short-term follow-through
12W Return
-9.5%
quarterly tape
Trend Breadth
51.9%
27 of 52 weeks active
Volume Ratio
0.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
6.6%
Latest completed week; four-week move 7.4%.
Indicator stack
29/35
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
11 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -0.6% below the Trend Line and sits at 50.9% of its 52-week range. The latest completed week returned 6.6%, after a 7.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2412-week average 0.55
12-week confirmation
Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.24Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 7.4% over four weeks, -9.5% over 12 weeks, and 11.3% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year27
Trend breadth51.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.85Latest activity-pressure read.
Pressure change8.2%Four-week change in activity pressure.
Leadership-7.13Latest relative-leadership reading.
RS change34.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 85%
Model confidence 68%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength9/100Blend of value, momentum, and quality. Underlying universe rank 92; rank 1 is best.
Value1/100Relative valuation strength. Underlying universe rank 100; rank 1 is best.
Quality7/100Profitability and accounting quality. Underlying universe rank 94; rank 1 is best.
Momentum82/100Medium-term price momentum. Underlying universe rank 19; rank 1 is best.
Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 1334.9x Price divided by trailing earnings.
- Price / sales
- 3.4x Market value relative to trailing revenue.
- EV / EBITDA
- 20.0x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -4.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 81.9% Gross profit retained from each unit of revenue.
- Operating margin
- 0.1% Operating profit retained from revenue.
- Free-cash-flow margin
- -13.7% Free cash flow generated from revenue.
- Return on invested capital
- 0.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 19.5% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -1.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 11 relevant articles.
1 positive · 10 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-15.0%Distance below the 52-week high.
13-week volatility5.9%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2612 weeks finished lower.
Best week+11.2%Week of 31 Jul.
Worst week-14.1%Week of 29 May.
Latest week+6.6%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains7
Flat weeks1
Modest losses6
Sharp losses6
Recent vol5.9%13-week weekly-return volatility.
Base vol5.2%52-week weekly-return volatility.
Up/down split23/21Count of positive and negative weeks in the 52-week window.
Average skew4.5% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGB Healthcare
4-week rank20 / 79
Group average0.0%
Trend breadth27.8%
Trend27.8%active weekly trend signals
MD44.3%positive activity pressure
RS22.8%positive relative leadership
Four-week leaders
IndustryGB Health Information Services
4-week rank5 / 9
Group average9.9%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD55.6%positive activity pressure
RS33.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape38/100
Trend, activity pressure, participation, and risk combine to a 38/100 tape read.
Indicator analysis22/100Latest 12-week confirmation: trend 2/12, activity pressure 2/12, relative leadership 1/12.
Activity pressure 0.24; No reversal markers Factors21/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 73; Small Cap Core rank 99 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 11 relevant articles.
Diaceutics PLC Reports Revenue Results for the Half Year Ended 30 June 2026 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 153.0 GBP | 6.6% | 153.9 GBP | 127.5 GBP | -0.85 | -7.13 | 564.6K | Off |
| 31 Jul 2026 | 143.5 GBP | 11.2% | 153.5 GBP | 127.0 GBP | -1.05 | -12.75 | 7.2M | Off |
| 24 Jul 2026 | 129.0 GBP | -4.4% | 153.0 GBP | 126.7 GBP | -1.16 | -20.75 | 305.0K | Off |
| 17 Jul 2026 | 135.0 GBP | -5.3% | 153.0 GBP | 126.4 GBP | -1.10 | -16.24 | 157.7K | Off |
| 10 Jul 2026 | 142.5 GBP | -2.4% | 152.8 GBP | 126.1 GBP | -0.93 | -10.90 | 146.9K | Off |
| 3 Jul 2026 | 146.0 GBP | 0.7% | 152.7 GBP | 125.8 GBP | -0.87 | -10.23 | 20.6K | Off |
| 26 Jun 2026 | 145.0 GBP | -2.0% | 152.3 GBP | 125.6 GBP | -0.86 | -9.34 | 18.1K | Off |
| 19 Jun 2026 | 148.0 GBP | 3.9% | 152.6 GBP | 125.3 GBP | -0.68 | -6.14 | 851.5K | Off |
| 12 Jun 2026 | 142.5 GBP | 0.7% | 153.1 GBP | 125.0 GBP | -0.43 | -10.45 | 484.1K | Off |
| 5 Jun 2026 | 141.5 GBP | -1.0% | 153.8 GBP | 124.7 GBP | -0.07 | -10.26 | 415.7K | Off |
| 29 May 2026 | 143.0 GBP | -14.1% | 154.5 GBP | 124.5 GBP | 0.42 | -9.77 | 1.5M | On |
| 22 May 2026 | 166.5 GBP | -1.5% | 155.3 GBP | 124.3 GBP | 0.56 | 4.23 | 119.2K | On |
| 15 May 2026 | 169.0 GBP | -4.2% | 155.2 GBP | 124.0 GBP | 0.75 | 8.60 | 124.6K | On |
| 8 May 2026 | 176.5 GBP | 6.6% | 154.9 GBP | 123.6 GBP | 0.76 | 13.34 | 763.4K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.